{"id":5220,"date":"2019-06-06T12:28:47","date_gmt":"2019-06-06T06:58:47","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=5220"},"modified":"2024-06-17T16:58:53","modified_gmt":"2024-06-17T11:28:53","slug":"the-business-cocktail-lti-03","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-lti-03","title":{"rendered":"The Business Cocktail"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a021db798225\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a021db798225\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-lti-03\/#Cancer_biotech_Inhibrx_files_for_USD_75_M_IPO\" >Cancer biotech Inhibrx files for USD 75 M IPO<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-lti-03\/#EpimAb_Biotherapeutics_raises_USD_74_M_to_accelerate_bispecific_pipeline\" >EpimAb Biotherapeutics raises USD 74 M to accelerate bispecific pipeline<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-lti-03\/#Columbia_University_Deerfield_forms_a_drug-development_alliance\" >Columbia University, Deerfield forms a drug-development alliance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-lti-03\/#Lung_Therapeutics_nets_USD_36_M_to_advance_its_clinical_assets\" >Lung Therapeutics nets USD 36 M to advance its clinical assets<\/a><\/li><\/ul><\/nav><\/div>\n\n<h4 class=\"wp-block-heading\" id=\"h-cancer-biotech-inhibrx-files-for-usd-75-m-ipo\"><span class=\"ez-toc-section\" id=\"Cancer_biotech_Inhibrx_files_for_USD_75_M_IPO\"><\/span><strong>Cancer biotech Inhibrx files for USD 75 M IPO<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>Celgene-partnered biotech <strong>Inhibrx <\/strong>aftersecuring USD 40 Million from Viking Global Investors, has filed\nfor <strong>USD 75 million IPO<\/strong>. Built on a\nsingle-domain antibody platform, it has three oncology programs in human\nclinical trials, a rare disease program, and two preclinical drugs. Inhibrx,\nhas also granted Italian-based <strong>Chiesi\nFarmaceutici<\/strong>, the rights for the development and commercialization of AAT-fusion\nprotein <strong>INBRX-101<\/strong>, outside of North\nAmerica. Chiesi will pay USD 10 million upfront and buy a USD 10 million worth\nof shares in Inhibrx. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-epimab-biotherapeutics-raises-usd-74-m-to-accelerate-bispecific-pipeline\"><span class=\"ez-toc-section\" id=\"EpimAb_Biotherapeutics_raises_USD_74_M_to_accelerate_bispecific_pipeline\"><\/span><strong>EpimAb Biotherapeutics raises USD 74 M to accelerate bispecific pipeline<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>EpimAb Biotherapeutics<\/strong>, a Shanghai-based biopharmaceutical company specializing in bispecific antibodies, today announced the closing of a<strong> USD 74 million <\/strong>Series B financing round. EpimAb secured funds from SDIC Fund, Sherpa Healthcare Partners and SCVC, 3E Bioventure Capital, Decheng Capital, Oriza Seed Capital and the Trend Investment Group. The company is deciding to use the funds to advance its bispecifics pipeline-based on its <strong>Fabs-in-Tandem Immunoglobin<\/strong> technology, abbreviated as Fit-IG. The company is also simultaneously working with U.K.-based <strong>Kymab<\/strong> and China\u2019s <strong>Innovent<\/strong> and <strong>Teruisi<\/strong>, mainly in <a href=\"https:\/\/www.delveinsight.com\/report-store\/gene-therapy-in-oncology-innovation-to-commercialization-competitive-landscape\">oncology <\/a>based areas. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-columbia-university-deerfield-forms-a-drug-development-alliance\"><span class=\"ez-toc-section\" id=\"Columbia_University_Deerfield_forms_a_drug-development_alliance\"><\/span><strong>Columbia University, Deerfield forms a drug-development alliance <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>Deerfield Management<\/strong>, a healthcare investment firm, and <strong>Columbia University <\/strong>have collaborated\nto form a research and development alliance. The team intends to accelerate the\ntranslation of biomedical discoveries into transformative treatments. Many\nuniversities just like Columbia University are trying to convert their research\nanalysis and insights into products and services.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-lung-therapeutics-nets-usd-36-m-to-advance-its-clinical-assets\"><span class=\"ez-toc-section\" id=\"Lung_Therapeutics_nets_USD_36_M_to_advance_its_clinical_assets\"><\/span><strong>Lung Therapeutics nets USD 36 M to advance its clinical assets <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>Lung Therapeutics <\/strong>has raised\u00a0<strong>USD 36 million<\/strong> in a Series C financing round\u00a0to take forward the treatment of serious lung complication. The company has decided to use the funds for the treatment of<strong> loculated pleural effusions<\/strong> (LPE), a serious complication of <a href=\"https:\/\/www.delveinsight.com\/report-store\/pneumonia-pneumococcal-market\">pneumonia<\/a>. The proceeds will also be spent to support Phase I clinical trials for another asset, <strong>LTI-03, <\/strong>a proenzyme that slowly gets activated in the lung, clearing scar tissues and promoting fluid drainage for the treatment of <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/idiopathic-pulmonary-fibrosis-market\" class=\"ek-link\">idiopathic pulmonary fibrosis<\/a><\/strong> (IPF). <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cancer biotech Inhibrx files for USD 75 M IPO Celgene-partnered biotech Inhibrx aftersecuring USD 40 Million from Viking Global Investors, has filed for USD 75 million IPO. Built on a single-domain antibody platform, it has three oncology programs in human clinical trials, a rare disease program, and two preclinical drugs. Inhibrx, has also granted Italian-based [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5221,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[137,4407],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-5220","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-cancer","tag-lung-therapeutics","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>The Business Cocktail 06\/06\/2019 - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"Lung Therapeutics has raised USD 36 million in a Series C financing round to take forward the treatment of serious lung complication...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-lti-03\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Business Cocktail 06\/06\/2019 - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"Lung Therapeutics has raised USD 36 million in a Series C financing round to take forward the treatment of serious lung complication...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-lti-03\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-06-06T06:58:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-06-17T11:28:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/06\/09021809\/Business-6-JUNE.png\" \/>\n\t<meta property=\"og:image:width\" content=\"750\" \/>\n\t<meta property=\"og:image:height\" content=\"410\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"The Business Cocktail 06\/06\/2019 - DelveInsight Business Research","description":"Lung Therapeutics has raised USD 36 million in a Series C financing round to take forward the treatment of serious lung complication...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-lti-03","og_locale":"en_US","og_type":"article","og_title":"The Business Cocktail 06\/06\/2019 - DelveInsight Business Research","og_description":"Lung Therapeutics has raised USD 36 million in a Series C financing round to take forward the treatment of serious lung complication...","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-lti-03","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-06-06T06:58:47+00:00","article_modified_time":"2024-06-17T11:28:53+00:00","og_image":[{"width":750,"height":410,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/06\/09021809\/Business-6-JUNE.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-lti-03","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-lti-03","name":"The Business Cocktail 06\/06\/2019 - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-lti-03#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-lti-03#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/06\/09021809\/Business-6-JUNE.png","datePublished":"2019-06-06T06:58:47+00:00","dateModified":"2024-06-17T11:28:53+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Lung Therapeutics has raised USD 36 million in a Series C financing round to take forward the treatment of serious lung complication...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-lti-03"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-lti-03#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/06\/09021809\/Business-6-JUNE.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/06\/09021809\/Business-6-JUNE.png","width":750,"height":410,"caption":"The Business cocktail"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/06\/09021809\/Business-6-JUNE-300x164.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Lung Therapeutics<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">Lung Therapeutics<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Jun 6, 2019","modified":"Updated on Jun 17, 2024"},"absolute_dates_time":{"created":"Posted on Jun 6, 2019 12:28 pm","modified":"Updated on Jun 17, 2024 4:58 pm"},"featured_img_caption":"The Business cocktail ","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5220","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=5220"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5220\/revisions"}],"predecessor-version":[{"id":28341,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5220\/revisions\/28341"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/5221"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=5220"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=5220"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=5220"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=5220"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=5220"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}